The Top 5 Biosimilars Articles for the Week of January 1

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 1, 2018.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 1.

Number 5: Many pharma companies rang in the new year with increases to their drugs’ list prices.

Number 4: The FDA has released new draft guidance for industry on good practices for submitting abbreviated new drug applications to speed generic drug approvals.

Number 3: New data show that LG Chem’s proposed biosimilar etanercept matches the reference Enbrel in terms of safety and efficacy.

Number 2: Drug maker Protalix announced positive phase 2 clinical data for an orally administered anti-TNF therapy.

Number 1: Momenta and Mylan have announced that they will begin clinical trials of M710, a proposed biosimilar to Eylea.

Finally, this week, contributor Brian Lehman explains why the so-called Medicare Part D “donut hole” creates an unintentional barrier to biosimilars in the United States. Read Lehman’s article and more content from expert contributors at